Pembrolizumab +/- Bevacizumab for Recurrent GBM
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California, Los Angeles
Los Angeles, California, United States
- University of California, San Francisco
San Francisco, California, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- Memorial Sloan-Kettering Cancer
New York, New York, United States
- Duke University Medical Center
Durham, North Carolina, United States
- Ut, Md Anderson Cancer Center
Houston, Texas, United States
- Huntsman Cancer Institute
Salt Lake City, Utah, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 9 Feb 2015
- Primary completion
- 28 Aug 2016
- Completion
- 14 Sept 2020
- Last update posted
- 22 Dec 2020
- Registered enrollment
- 80
- Registry id
- NCT02337491
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.